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OBJECTIVE—Mesenchymal stem cells (MSCs) contribute to
endothelial cell (EC) migration by producing proteases, thereby
paving the way into the tissues for ECs. MSCs were added to our
previously described composite EC islets as a potential means to
improve their capacity for islet angiogenesis.
RESEARCH DESIGN AND METHODS—Human islets were
coated with primary human bone marrow–derived MSCs and
dermal microvascular ECs. The capacity of ECs, with or without
MSCs, to adhere to and grow into human islets was analyzed. The
survival and functionality of these composite islets were evalu-
ated in a dynamic perifusion assay, and their capacity for
angiogenesis in vitro was assessed in a three-dimensional ﬁbrin
gel assay.
RESULTS—ECs proliferated after culture in MSC-conditioned
medium, and MSCs improved the EC coverage threefold com-
pared with EC islets alone. Islet survival in vitro and the
functionality of the composite islets after culture were equal to
those of control islets. The EC-MSC islets showed a twofold
increase in total sprout formation compared with EC islets, and
vascular sprouts emanating from the EC-MSC–islet surface
showed migration of ECs into the islets and also into the
surrounding matrix, either alone or in concert with MSCs.
CONCLUSIONS—EC proliferation, sprout formation, and in-
growth of ECs into the islets were enhanced by MSCs. The use of
composite EC-MSC islets may have beneﬁcial effects on revas-
cularization and immune regulation. The technique presented
allows for pretreatment of donor islets with recipient-derived
ECs and MSCs as a means of improving islet engraftment.
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T
he islets of Langerhans are micro-organs, with
afferent and efferent blood vessels connecting
the capillary network of the islets to the circula-
tion system (1). Intra-islet endothelial cells
(ECs) are fenestrated, and the density of the capillary
network in the islets is 10 times higher than that of the
surrounding exocrine tissue (2,3). During the process of
islet isolation before transplantation, the ECs in the islets
lose their external vascular support; this situation contrib-
utes to their dedifferentiation, apoptosis, and necrosis
during subsequent in vitro culture (4).
The formation of new capillaries during revasculariza-
tion is a complex process that involves digestion of the
vascular wall by proteases and the migration, prolifera-
tion, and differentiation of ECs (5). When blood vessels are
assembled, ECs produce platelet-derived growth factor,
which attracts supportive cells, including mesenchymal
stem cells (MSCs) that can differentiate into pericytes (6).
We hypothesized that adding MSCs to our previously
described composite EC islets (7) might improve the
adherence of the ECs to the islets and subsequent vascu-
larization because MSCs contribute to EC migration by
producing proteases, thereby paving the way into the
surrounding tissue for the immature EC sprouts (8). MSCs
have also been shown to upregulate the expression of
angiopoietin and vascular endothelial growth factor
(VEGF) in ECs, contributing to an increase in angiogenesis
and stabilization of the vasculature (9). Moreover, MSCs
have been shown to possess important immune-modulat-
ing properties (10), and they do not trigger adaptive
immune reactions, which could make them ideal in islet
transplantation setting (11,12).
The present study describes a gentle and reproducible
technique for forming EC-MSC islets that is designed to
take into consideration the inherent characteristics of the
various cell types involved and to take advantage of the
anchorage-dependent growth of ECs and MSCs. Our data
demonstrate that addition of MSCs to our composite islets
enhanced the capacity of ECs to enclose the islets without
compromising the functionality of the islets. Importantly,
the MSCs stimulated EC sprout formation not only into the
surrounding matrices, but also into the islets where intra-
islet capillary-like structures were formed.
RESEARCH DESIGN AND METHODS
Isolation of islets of Langerhans. Human islets of Langerhans were isolated
at the Division of Clinical Immunology at Uppsala University by using a
modiﬁed semi-automated digestion-ﬁltration method, then cultured in CMRL-
1066 with supplements (islet medium) (13–15).
Islets were released for research after approval by the ethics committee at
Uppsala University Hospital. Pancreata from 20 donors were used (4–7
donors per experiment). The purity of the islet preparations was 75–95%, with
the exception of one preparation that was 45% pure.
Cell culture. MSCs were isolated from human adult bone marrow as
previously described (10). In brief, bone marrow was harvested from the iliac
crest of adult volunteers (n  8) after approval from the ethics committee at
Huddinge University Hospital. The cells were classiﬁed as MSCs on the basis
of their ability to differentiate into bone, fat, and cartilage and by ﬂow
cytometric analysis (positive for CD29, CD44, CD73, CD166, and CD105, but
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DIABETES, VOL. 57, SEPTEMBER 2008 2393negative for CD14, CD34, and CD45) and were used from passage 3-9
(FACScalibur; Becton Dickinson, Franklin Lakes, NJ). Potential EC contami-
nation of the MSC population was assessed by ﬂow cytometry (Becton
Dickinson) (n  3). The cells were stained for CD90 (1:100; BD Bioscience
Pharmingen, San Diego, CA), the EC pan marker CD31 (1:100; Becton
Dickinson), and the lectin Ulex europeaus agglutinin-1 (UEA-1, 1:100; Vector
Laboratories, Peterborough, U.K.). Human dermal microvascular ECs
HDMECs (PromoCell, Heidelberg, Germany) derived from adult dermis were
cultured on 1% gelatin-coated ﬂasks in EC Growth Medium Microvascular
with supplements (EC medium; PromoCell). The ECs were used from passage
3-12.
Cell labeling. MSCs and ECs were labeled using CellTracker (CT) green and
CT orange CMRA, respectively, according to the manufacturer’s protocol
(Molecular Probes, Eugene, OR).
Thymidine assay and coculture of cells. Thymidine assays were performed
according to a standard proliferation protocol measuring [
3H]thymidine
(1Ci/ml) incorporation (16). ECs were plated in 24-well plates, with 25  10
3
cells/well in EC medium with supplements for 24 h and then cultured in EC
medium without supplements but containing 0.5% fetal bovine serum (starva-
tion medium) for an additional 24 h (basal control) or stimulated with either
VEGF-A (20 ng/ml; Peprotech, London, U.K.) in starvation medium or MSC-
conditioned medium (supernatant from 24-h MSC cultures in starvation
medium). [
3H]thymidine incorporation (at 20–24 h) was determined by liquid
scintillation counting. Triplicate samples were assayed in three individual
experiments. A mixture of 25  10
3 CT green–labeled MSCs and 25  10
3 CT
orange–labeled ECs were cocultured in eight-well glass culture slides (Becton
Dickinson) with EC medium and analyzed by ﬂuorescence microscopy after
3 days.
Coating of islets of Langerhans with ECs and MSCs. Islets of Langerhans
(10,000–30,000 islet equivalents) were incubated within 2–5 days after isola-
tion with 0.5  10
6 CT orange–labeled ECs (EC islets) or with 0.25  10
6 CT
green–labeled MSCs in combination with 0.25  10
6 CT orange–labeled ECs
(EC-MSC islets) in a total volume of 500 l. The cell suspensions were
incubated at 37°C for 2–3 h in suspension culture tubes in EC medium and
mixed gently twice per hour during the incubation. Thereafter, the EC islets,
EC-MSC islets, and untreated control islets were cultured for up to 6 days at
37°C in EC medium or islet medium (CMRL; Invitrogen) until analyzed. The
medium was changed every second day. Quantiﬁcation of EC adherence was
performed on EC islets and EC-MSC islets after 1 and 4 days of culture.
In vitro islet survival assay and cytokine and insulin content determi-
nation. A total of 100 islets per donor (n  6) were hand picked: 50 islets
were coated with 5  10
3 MSCs and 5  10
3 ECs, and 50 islets were untreated.
All islets were cultured for 6 days in EC medium, with a medium change every
second day. The number of remaining islets in the respective groups were
counted after 1, 3, and 6 days of culture, and the islet number was conﬁrmed
after 6 days by dithizone staining (18). Control and EC-MSC islets were
collected after 6 days of culture. Total DNA (Picogreen; Invitrogen), interleu-
kin (IL)-8, IL-6 (R&D Systems, Oxford, U.K.), monocyte chemotactic protein-1
(MCP-1) (Serotec, Oxford, U.K.), tissue factor (TF) (Imubind; American
Diagnostica, Stamford, CT), and insulin (Mercodia) contents were measured
on a Gyrolab workstation (Gyros, Uppsala, Sweden), and the values were
divided with total DNA. Four or more different islet isolations with 20 islets in
each condition were analyzed.
Dynamic perifusion. The functionality of the islets coated with EC-MSC and
of untreated islets from the same isolation was tested at different time points
after coating (at 24 h and day 3–4). EC medium was used during the ﬁrst 24 h
of suspension culture; thereafter, the medium was changed to islet medium
with supplements (17). Islets were challenged in a dynamic perifusion system,
beginning with a low glucose concentration (1.67 mmol/l) during the ﬁrst 36
min, followed by a high-glucose challenge (20 mmol/l) for 42 min, then
reexposure to the low glucose concentration during the last 48 min. Fractions
were collected at 6-min intervals over 126 min and analyzed for insulin content
using commercial ELISA kits (Mercodia Insulin ELISA; Mercodia, Uppsala,
Sweden). The area under the curve was calculated to evaluate the insulin
secretion during high glucose stimulation with subtracted basal insulin
secretion. Four different islet isolations with 20 islets in each condition were
analyzed.
Fibrin gel in vitro angiogenesis assay. Control, EC, and EC-MSC islets
were placed between two layers of ﬁbrin gel (2.5 mg/ml ﬁbrinogen and 2 g/ml
thrombin; Sigma-Aldrich, St. Louis, MO). After polymerization, EC medium
supplemented with VEGF (30 ng/ml; Peprotech) was added. The islet prepa-
rations (n  6) were cultured for 24 h, 48 h, and 3–4 days and then ﬁxed in 4%
paraformaldehyde. Sprouts were counted manually by the same person
(blinded to the composition of the islet preparation), and 4–20 islets were
counted per group in each experiment. The EC sprout length was measured
using Leica Qwin software (Leica Microsystems, Nussloch, Germany) on
pictures taken on day 4 of EC and EC-MSC islets in ﬁbrin gel. The total EC
sprout length per islet was calculated for each experiment (groups of 2–10
islets, n  6). The mean total sprout length per islet for all the experiments
(n  6) was then calculated. The frequencies of the various sprout types were
calculated by analyzing micrographs of EC-MSC islets from the ﬁbrin gel
experiments (n  6).
Immunohistochemical staining. Composite and control islets were ﬁxed in
4% paraformaldehyde for 30 min, washed in PBS, and incubated in 20%
sucrose/PBS overnight at 4°C, then embedded in optimal cutting temperature
medium (Tissue Tech; Sakura Finetek, Zoeterwoude, Netherlands), frozen,
cryosectioned, and permeabilized in 0.3% Triton X-100/PBS for 15 min.
Immunohistochemical staining was performed using guinea pig anti-human
insulin (1:400; Fitzgerald Industries International, Concord, MA) followed by
Alexa Fluor 488-labeled goat anti-rabbit (1:1,000; Molecular Probes) or Alexa
Fluor 488–conjugated mouse anti-human CD31 (1:100; Becton Dickinson).
Counterstaining was performed with DAPI (10 g/ml; Sigma-Aldrich).
Production of DsRed-expressing lentiviral particles and lentiviral vec-
tor infection of ECs. Stocks of Discosoma species–derived red ﬂuorescent
(DsRed)–expressing lentiviral vectors (Lv-DsRed) were produced by cotrans-
fection of three plasmids, the viral core packaging construct pCMVdeltaR8.74,
the VSV-G envelope protein vector pMDG.2, and the transfer vector pRRLsin-
PPThCMV-MCS-wpre containing DsRed cDNA (a gift of W.T. Hendriks), into
human embryonic kidney 293T cells as previously described (19,20).
HDMECs at passage 3 were seeded onto 1% gelatin-coated six-well plates
(1  10
5 cells/well; AH Diagnostics) and cultured for 48 h. Virus at a titer of
2 10
5 TU/ml Lv-DsRed was added to the subconﬂuent cells in combination
with 2 g/ml Sequa-Brene (Sigma-Aldrich) in EC medium. The plate was spun
for 60 min during the Lv-DsRed infection of the ECs, and, thereafter,
additional fresh medium was added to the cells. The DsRed ECs were then
used in the long-term islet culture experiments according to the previously
described protocol for coating of islets.
Image analysis and quantiﬁcation. Coating, morphology, and sprout anal-
yses were performed using confocal laser scanning microscopy (Zeiss LSM
510 Meta; Carl Zeiss International, Oberkochen, Germany) and/or ﬂuores-
cence microscopy (Nikon Elipse E600, Nikon TS100; Nikon, Tokyo, Japan).
Confocal z-stack images composed of 10 pictures were merged to produce a
picture for use in analyzing EC adherence. Micrographs were analyzed using
Leica Qwin software (Leica microsystems) to determine the surface area and
total sprout length. The frequency of particular types of sprout composition
was calculated from pictures using Adobe Photoshop software. Quantiﬁcation
of islet number was accomplished by the use of a stereomicroscope (Leica
Microsystems), and pictures were analyzed using Adobe Photoshop software.
Ingrowth of DsRed ECs into the islets was evaluated using confocal micros-
copy z-stack images, visualizing ECs at a deﬁned depth of 30 m into the islets
after 3 or 6 days of culture, with a majority of samples being analyzed after 6
days. A deﬁned distance of 30 m from the islet surface was chosen to yield
good confocal resolution. The presence of ECs was scored as 0–3, with 0
indicating the absence of ECs from the islet section and scores of 1–3
indicating a scarce (1), intermediate (2), or abundant (3) amount of ECs
present.
Statistical analysis. Data are presented as means  SEM. Mean values were
compared using a two-tailed Wilcoxon test for paired data, with signiﬁcance
set at P  0.05.
RESULTS
Interaction between ECs and MSCs. Before coculture,
the purity of each cell population (EC and MSC) was
assessed by ﬂuorescence-activated cell sorter analysis.
This analysis showed that the MSCs stained positive for
the stem cell marker CD90 but were negative for the EC
marker CD31 and did not bind the human EC lectin UEA-1
(Fig. 1A), indicating an absence of contaminating ECs.
The ECs were negative for CD90 but were positive for
CD31 and bound UEA-1 (Fig. 1B). MSC-conditioned
medium induced an increase in EC proliferation, with
the magnitude of the increase being similar to that
produced by the addition of 20 ng/ml VEGF-A to the
culture medium (Fig. 1C).
To analyze the potential cell growth effects by MSCs on
ECs, we cocultured MSCs (CT green) and ECs (CT orange)
in EC medium at deﬁned cell densities for 3 days. Morpho-
logical analysis of these cultures showed that the cells
grew either on top of each other or aligned with one
another, indicating interactions between the cells (Fig.
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nomenon, indicating unusual growth interactions between
the ECs and MSCs.
Improved islet coating by combining ECs and MSCs.
ECs are adherent cells that interact with the extracellular
matrix. We therefore evaluated the adherence of ECs (CT
orange) and MSCs (CT green) to isolated islets. After 3-h
incubation of islets and ECs (EC islets), a few ECs were
found to adhere to the islet surface (Fig. 2A, left panel).
Combining ECs and islets with MSCs (EC-MSC islets) had
no apparent effect on the coating of the islets by ECs at
this early time point (Fig. 2A, right panel). However, after
only 1 day of incubation, a threefold increase in the islet
surface covered by ECs was observed in the presence of
MSCs, as compared with EC islets (Fig. 2B, quantiﬁcation
in Fig. 2C). Morphological characterization of the ECs
adhering to the islet surface repeatedly showed that the
ECs ﬂattened out and aligned themselves with the surface
of the islets in the presence of MSCs (Fig. 2D). Analyses of
sectioned EC islets and EC-MSC islets stained for insulin
showed ECs adhering to both insulin-positive and insulin-
negative cells in the islet preparations after 24 h of
incubation (Fig. 2E–G). After 4 days in suspension culture,
there was a tendency toward a decrease in the islet surface
area covered by ECs in both EC islets and EC-MSC islets;
however, this difference did not reach statistical signiﬁ-
cance (n  6; P  0.16 and P  0.06, respectively). A few
cell clusters remained uncoated in all groups (Fig. 2B,
right panel, arrowheads).
EC islet and EC-MSC islet survival and function. Islet
loss during the process of coating was evaluated by
incubation of 50 hand-picked islets with ECs and MSCs
according to the coating protocol. No loss of islets was
observed during the formation of EC-MSC islets; however,
a gradual decrease of 20% in islet number was observed
in both groups during the 6-day culture period (Fig. 3A).
Cytokine analysis showed insigniﬁcant differences in the
levels of IL-6 (0.005  0.005, 0.07  0.06 pmol/g DNA),
IL-8 (0.3  0.1, 0.9  0.04 pmol/g DNA), TF (0.1  0.01,
0.3  0.07 pmol/g DNA) and MCP-1 (0.2  0.2, 0.6  0.1
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FIG. 1. Interactions between ECs and MSCs. Expression of CD90 (green line) and CD31 (orange line) and binding of UEA-1 (red line) to MSC
(green, A) and EC (red, B), as assessed by ﬂow cytometry (A and B show representative results of three experiments). C: EC proliferation in
basal (gray), MSC-conditioned (white), or VEGF (black) medium. Results are expressed as the percentage of the basal response (means  SEM)
from three separate experiments performed in triplicate. D: Coculture of MSCs (green) and ECs (red). The cells grew either on top of one another
(D, arrow) or aligned with each other (D, arrowhead). Scale bars  50 m. (Please see http://dx.doi.org/10.2337/db07-0981 for a high-quality
digital representation of this ﬁgure.)
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tively. The insulin content/DNA was 1.5  0.4 ng insulin/ng
DNA for the control islets and 0.9  0.3 ng insulin/ng DNA
for the EC-MSC islets on day 6.
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FIG. 3. Islet numbers, functionality, and dynamic insulin release of EC-MSC islets. Control islets (black) and EC-MSC islets (white) were counted
after 1, 3, and 6 days (A) (mean of islet number  SEM; n  6; *P  0.03; when the numbers of control islets on day 6 were compared with those
of control islets on day 1). Insulin release was measured from control islets (black) and EC-MSC islets (white) cultured for 1 day (B) or 3–4 days
(C). B and C show means  SEM, n  4.
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dynamics during high-glucose stimulation after 1 and 3–4
days compared with control islets (Fig. 3B–C). No signif-
icant differences were seen in the stimulation indexes
between control islets and EC-MSC islets at 1 day (5,090 
2,190 and 4,540  1,300 pmol  min
1  l
1, respectively) or
3–4 days of culture (4,560  1,330 and 5,090  800 pmol 
min
1  l
1, respectively).
Sprouting and invasion of ﬁbrin gels. To evaluate the
effect of angiogenesis, uncoated and coated islets were
cultured in three-dimensional ﬁbrin gels (Fig. 4A and
C–D), in which ECs formed deﬁned sprouts of patched
ECs, and MSCs formed thin cords of aligned cells (21,22).
After only 48 h, the total number of sprouts in the
composite EC-MSC islets was higher than that in the
control or EC islets. This difference remained after 3–4
days of culture (Fig. 4B).
When the islets came into close contact with each other,
sprouts of ECs were formed between the EC-MSC islets,
indicating paracrine stimulation (Fig. 4C, arrowhead).
EC-MSC islets retained sprout formation over time,
whereas in EC islets, the sprouts were disrupted and the
ECs were separated from the islets (Fig. 4C–D). The
median ( 1 quartile) EC sprout length in the EC-MSC
islets was 900 m (700–1,380 m) and only 680 m
(300–840 m) in the EC islets. Also, the total EC sprout
length per islet was longer in the EC-MSC islets than in the
EC islets (Fig. 4E).
Figure 5 shows the typical morphology of sprouts
emanating from a composite EC-MSC islet after 2 days in
culture. At this early stage, the sprouting was character-
ized by a complex course of events involving EC sprouts
interacting with MSCs at the EC sprout base (Fig. 5A), ECs
in close contact with MSCs (Fig. 5B–C), ECs at the leading
tip of an MSC-initiated sprout (Fig. 5D), and MSCs at the
leading tip of an EC sprout (Fig. 5E). ECs also migrated in
groups to form a completely naked sprout with no appar-
ent connection to the islet (Fig. 5F). Sprouts of ECs in
close interaction with MSCs occurred twice as frequently
as EC sprouts with nonaligned MSC cords. In the sprouts
in which close cell interactions occurred between ECs and
MSCs, there was a preference for ECs as the leading tip
cells.
Vessel formation in islets coated with ECs and MSCs.
After 24 h of culture in EC medium, the EC islets were
stained for CD31 to reveal endogenous islet capillaries
(Fig. 6A, green). An ingrowth of added ECs (CT orange)
connecting to the native CD31-positive islet capillary net-
work was frequently observed (Fig. 6A, arrowheads). To
achieve a stable expression of DsRed, we infected the ECs
with DsRed-labeled lentiviral particles. DsRed-infected
ECs showed almost complete transduction after 2 weeks
of culture, as visualized by merged phase-contrast and
ﬂuorescence microscopy images (Fig. 6B). The prolifera-
tive capacity of the DsRed EC in response to VEGF was
unaffected (data not shown).
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DsRed EC-MSC islets after 6 days of suspension culture
showed that the DsRed ECs had penetrated into the islets
(Fig. 6C). Especially in the EC-MSC islets, the DsRed ECs
had formed a dense network of capillary-like structures
penetrating into the islets (Fig. 6D). The presence of
DsRed ECs within the islets was scored at day 3 and 6.
Whereas the EC islets had a mean score of 0.7  0.2, the
EC-MSC islets showed a higher level of penetration, with a
mean score of 1.6  0.4 (Fig. 6E). A comparison of the
score distribution for the EC islets and EC-MSC islets
showed that those with a score of 0 or 1 were predomi-
nantly EC islets, whereas the islets reaching a score of 2 or
3 were predominantly EC-MSC islets (Fig. 6F).
DISCUSSION
In the present study, modern tissue engineering was
applied as a strategy to enhance the process of islet
angiogenesis by combining ECs and supportive MSCs with
isolated islets in culture. The capacity of the ECs to cover
the islet surface was markedly enhanced by the presence
of MSCs. This effect is most likely not only a result of
enhanced adherence, but also a reﬂection of a change in
the phenotype of the ECs that allowed them to stretch
toward and interact with the islet surface, together with an
increase in their proliferation. Importantly, in an estab-
lished in vitro model of angiogenesis, the MSCs also
stimulated EC sprout formation, not only into the sur-
rounding matrices, but also into the islets where intra-islet
capillary-like structures were formed.
Microvascular ECs were used to obtain an active EC
phenotype with a capacity for angiogenesis that resembles
a tentative future clinical situation involving harvesting
autologous ECs from fat tissue (23). As compared with the
aortic ECs that were used earlier (7), microvascular ECs
are less covered by pericytes and, therefore, relatively
more susceptible to remodeling (24). The relative capacity
of EC populations to coat microcarrier surfaces is affected
by the source from which they were obtained (25) and
their expression of integrins, such as 5 1, 1 1, and v
5. The same relationship, possibly reﬂecting variations in
integrin expression (25), seems to hold true for their
ability to coat islet surfaces (cf. [7]).
Established in vitro models of angiogenesis involve
culturing ECs in three-dimensional polymers, such as
ﬁbrin or collagen gels (26,27). By using this model system,
we were able to demonstrate the induction of sprout
formation of ECs in the presence of MSCs, a response that
could be monitored over time by confocal microscopy.
Similarly, Ghajar and colleagues (8) have demonstrated
stimulatory effects of MSCs on angiogenesis in three-
dimensional ﬁbrin gels. The induced vessel formation was
due in part to degradation of the ﬁbrin matrix by proteases
produced by the MSCs, and sprout formation was en-
hanced even in matrices in which the matrix density was
too high for the ECs to invade when cultured alone (8).
This capacity of MSCs may be of particular importance in
facilitating EC migration into dense micro-organs such as
islets. In addition, MSCs most likely contributed growth
factors and extracellular matrix production that serve to
encourage the stabilization and maturation of the EC
sprouts (9). This effect of MSCs was evidenced by the
increased sprout formation by EC-MSC islets in ﬁbrin gels,
where close interactions between EC sprouts and MSCs
occurred to a high degree. The MSCs express platelet-
derived growth factor (PDGF) receptors and may respond
to PDGF production by the ECs, leading to enhanced cell
interactions (6,28). A majority of the EC sprouts that
interacted closely with MSCs in the ﬁbrin gel also showed
a thicker sprout phenotype, suggesting that a maturation
process occurred. In contrast, several of the sprouts
emanating from the EC islets eventually collapsed and
detached from their base at the islet surface.
Examination of sections of composite islets showed that
the added ECs formed connections to the native islet
capillaries. This growth of ECs into the islets was analyzed
by scoring confocal microscopy z-stacks. A marked in-
crease in the number of ECs growing into the islets was
observed in the presence of MSCs. In these samples, the
ECs formed capillary-like structures deep within the EC-
MSC islets, indicating a prompt and enhanced angiogenic
capacity.
The technique described here for forming EC-MSC islets
has been designed to take into consideration the speciﬁc
needs for in vitro support of the various cell types involved
and to take advantage of the anchorage-dependent growth
EC MSC
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FIG. 5. Confocal scanning of sprout formation from composite islets with ECs and MSCs showing islets coated with MSC (green) and EC (red)
cultured in three-dimensional ﬁbrin gel (enlarged pictures to the right). A–F: MSCs at the base of an endothelial sprout (A), MSCs and ECs in
close contact (B), ECs and MSCs growing side-by-side (C), an endothelial sprout tip (D), an MSC cord tip (E), and a naked, unconnected
endothelial sprout (F). Scale bars  100 m. (Please see http://dx.doi.org/10.2337/db07-0981 for a high-quality digital representation of this
ﬁgure.)
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FIG. 6. Analysis of intra-islet vessel formation by accompanying ECs. Sectioned islets, coated with EC (red) and stained for CD31 (green), showed
connections between accompanying EC and intra-islet capillaries (A, arrowheads). Yellow-colored vessels indicate CD31-positivity on added ECs. The
last ﬁgure in panel A shows an enlargement of the connecting ECs. The merged phase-contrast and DsRed ﬂuorescence microscope images/micrographs
of infected human dermal microvascular ECs show an almost complete transduction efﬁciency with the DsRed lentiviral vector (B). Cand D: DsRed ECs
visualized in composite islets after 6 days of culture, EC islets alone (C), and EC islets in the presence of unlabeled MSCs (D). The insert in the last
panel shows islets in bright-ﬁeld with a DsRed EC overlay. Scale bars in A  50 m. Scale bars in B–D  100 m. Scoring of DsRed ECs in the islets
showed an increased EC ingrowth in EC-MSC islets (white) compared with EC islets (black) (E) (mean score  SEM; n  7; *P  0.03). F: Score
distribution for DsRed EC ingrowth into EC-MSC islets (white), as compared with EC islets (black). (Please see http://dx.doi.org/10.2337/db07-0981
for a high-quality digital representation of this ﬁgure.)
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DIABETES, VOL. 57, SEPTEMBER 2008 2399of ECs and MSCs. By utilizing the inherent characteristics
of the different cell types, we were able to establish a
gentle and reproducible technique. Most importantly, no
additional loss of islets occurred during the formation of
EC-MSC islets and their subsequent culture (6 days), when
compared with untreated islets. A culture medium de-
signed to support microvascular EC survival was applied
to promote EC adhesion and proliferation on the islet
surface unaffecting the islet function. Equally important is
that the culture conditions applied did not promote the
pro-inﬂammatory and procoagulant capacity of ECs
(29,30), i.e, there was no difference in the level of expres-
sion of TF, IL-6, IL-8, or MCP-1 between the EC-MSC and
control islets.
In the present communication, human ECs, MSCs, and
islets were used. One limitation of this approach in the
experimental setting is that evaluation of composite EC-
MSC islet grafts in small animal models are not easily
performed because of several signiﬁcant species-speciﬁc
differences in important areas such as angiogenesis, tissue
repair, and innate immunity (31). Also, severely immuno-
deﬁcient mice (SCID, nu/nu, and Rag) trigger strong innate
immune responses that mainly target the vasculature of a
transplanted organ due to the phylogenetic disparity be-
tween the two species, i.e., human-to-mouse is a discor-
dant xenotransplantation model triggering activation of
neutrophils, natural killer cells, macrophages, the comple-
ment and coagulation systems, and naturally occurring
xenoreactive antibodies (32–39).
MSCs are currently being evaluated in clinical trials for
their capacity to control severe graft-versus-host disease
(40). Composite EC-MSC islet grafts could beneﬁt from the
immune regulatory effects of MSCs and from improved
revascularization, thereby promoting transplantation at an
extrahepatic site. This strategy requires a reliable source
of recipient-derived ECs or endothelial precursor cells;
however, human endothelial precursor cells can be ob-
tained in relatively large numbers by sorting for circulating
angiopoietin receptor Tie-2-positive cells (41) or from
adipose-derived stem cells in human fat tissue (42,43). Our
promising results with EC-MSC islets strongly suggest that
they can contribute to the success of future clinical islet
transplantation.
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